Physician profile
Tripti Singh
NPI 1528218781
$13,369.28
in general payments reported to CMS, 2019-2025
12 companies · $6,445 in 2025
The $6,445 reported for 2025 was more than what 94% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,627 · 2022: $148 · 2023: $75.26 · 2024: $3,074 · 2025: $6,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,520 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,500 · Food and Beverage: $575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,520.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,500.00 |
| Food and Beverage | $574.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $3,809.91 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $3,627.06 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,920.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $2,717.99 | 2025 | |
| Apellis Pharmaceuticals, INC. | $141.38 | 2025 | Empaveli |
| Outset Medical INC | $75.26 | 2023 | |
| Calliditas Therapeutics US INC. | $55.10 | 2024 | |
| Fresenius USA Marketing, INC. | $22.58 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tripti Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.